Learning slopes in early-onset Alzheimer's disease
- PMID: 37243937
- PMCID: PMC10806757
- DOI: 10.1002/alz.13159
Learning slopes in early-onset Alzheimer's disease
Abstract
Objective: Investigation of learning slopes in early-onset dementias has been limited. The current study aimed to highlight the sensitivity of learning slopes to discriminate disease severity in cognitively normal participants and those diagnosed with early-onset dementia with and without β-amyloid positivity METHOD: Data from 310 participants in the Longitudinal Early-Onset Alzheimer's Disease Study (aged 41 to 65) were used to calculate learning slope metrics. Learning slopes among diagnostic groups were compared, and the relationships of slopes with standard memory measures were determined RESULTS: Worse learning slopes were associated with more severe disease states, even after controlling for demographics, total learning, and cognitive severity. A particular metric-the learning ratio (LR)-outperformed other learning slope calculations across analyses CONCLUSIONS: Learning slopes appear to be sensitive to early-onset dementias, even when controlling for the effect of total learning and cognitive severity. The LR may be the learning measure of choice for such analyses.
Highlights: Learning is impaired in amyloid-positive EOAD, beyond cognitive severity scores alone. Amyloid-positive EOAD participants perform worse on learning slopes than amyloid-negative participants. Learning ratio appears to be the learning metric of choice for EOAD participants.
Keywords: early-onset Alzheimer's disease; learning slopes; memory.
© 2023 the Alzheimer's Association.
Conflict of interest statement
CONFLICT OF INTEREST STATEMENT
No authors associated with this project have reported conflicts of interest that would impact these results. Author disclosures are available in the supporting information.
References
-
- Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dementia. 2021;17:327–406. - PubMed
-
- Palasi A, Gutierrez-Iglesias B, Alegret M, et al. Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol. 2015;262:1238–1246. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R56 AG057195/AG/NIA NIH HHS/United States
- P30 AG072980/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- P30AG066506/AG/NIA NIH HHS/United States
- AARG-22-926940/ALZ/Alzheimer's Association/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- R01 AG079170/AG/NIA NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States
- U24AG021886/AG/NIA NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- LDRFP-21-818464/ALZ/Alzheimer's Association/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- U24 AG021886/AG/NIA NIH HHS/United States
- P50AG047366/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- R01 AG072120/AG/NIA NIH HHS/United States
- P30 AG066515/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- LEADS GENETICS-19-639372/ALZ/Alzheimer's Association/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- P30 AG066506/AG/NIA NIH HHS/United States
- R56 AG057195/ALZ/Alzheimer's Association/United States
- P30 AG072976/AG/NIA NIH HHS/United States
